A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Gum disease appears to disrupt brain activity, potentially increasing a person's risk of cognitive decline. People with gum ...

Gum disease appears to disrupt brain activity, potentially increasing a person's risk of cognitive decline. People with gum ...

The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

These sleep aflictions are now recognised in most cases of early dementia – this new discovery could lead to earlier detection ...

Groundbreaking research reveals potential link between cytomegalovirus (CMV) and Alzheimer's disease, offering new insights ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizo ...